{
    "nct_id": "NCT05483868",
    "official_title": "A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer",
    "inclusion_criteria": "1. Confirmed diagnosis urothelial carcinoma of the bladder (Recurrence of prior NMIBC biopsy or pathology must be obtained within 12 months prior to enrollment. First time NMIBC biopsy within 6 months of screening. MIBC allowed if demonstrated pathologically)\n2. Have no evidence of metastatic disease\n3. Adequate bone marrow, renal, and hepatic function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Any additional malignancy that requires active treatment. Exceptions include:\n\n   1. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy with evidence of remission for at least 1 year.\n   2. In situ cervical cancer treated and with at least 1 year without recurrence.\n   3. Any other subject felt appropriate by the Investigator upon discussion with trial's Medical Monitor.\n2. Used an investigational drug or medical device within 30 days or 5 half-lives (whichever is longer) of Visit 1 or be concurrently enrolled in another investigational trial.\n3. Active bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy and subject must be off all systemic anti-infective agents.\n4. Chronic active hepatitis B or C and HIV.",
    "miscellaneous_criteria": ""
}